Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Treating Intrabony Defect With MINST VS MINST Extended PRF

NCT07836231 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-05-26
Last updated
2026-09-23

Condition(s) studied

Periodontal Intrabony Defects

Investigational drug(s) / intervention(s)

Extended Platelet-Rich Fibrin (e-PRF)Modified Minimally Invasive Non-Surgical Technique (MINST)

Extended Platelet-Rich Fibrin (e-PRF): Autologous extended platelet-rich fibrin (e-PRF) prepared from the participant's peripheral blood. Whole blood is centrifuged to obtain liquid platelet-rich fibrin, while the platelet-poor plasma is heated to form denatured albumin gel. The cooled albumin gel is mixed with the liquid platelet-rich fibrin to produce e-PRF, which is applied into the periodontal intrabony defect immediately after completion of the MINST procedure

Modified Minimally Invasive Non-Surgical Technique (MINST): Modified minimally invasive non-surgical periodontal therapy performed under local anesthesia using piezoelectric ultrasonic instruments with thin tips and magnification loupes. The procedure aims to thoroughly debride the periodontal pocket while minimizing soft tissue trauma and preserving root cementum by avoiding intentional root surface smoothing and gingival curettage.

Study summary

This study evaluates a minimally invasive non-surgical technique (MINST) for treating periodontal intrabony defects, with or without the addition of Extended Platelet-Rich Fibrin (e-PRF). The goal is to determine which approach provides better bone regeneration and gum healing.

Study Procedures

Control Group:

Local anesthesia by infiltration at the treatment site

Instrumentation of the root surface up to the bottom of the periodontal pocket

Efforts are made to minimize trauma to soft tissues and interdental papilla using subpapillary access

Cleaning is performed using piezo-electric devices with delicate tips, avoiding aggressive root smoothing or gingival curettage

3-4× magnification loupes are used to improve precision

Intervention Group:

All the above procedures

Followed by injection of e-PRF, a preparation derived from the patient's own blood

Blood is collected in 4 mL tubes and centrifuged at 700 g for 8 minutes

The platelet-poor plasma is heated to create an albumin gel

The remaining buffy coat (rich in platelets and growth factors) is mixed with the cooled albumin gel to form Alb-PRF, which is applied to the defect

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Adults aged above 21 years. Clinical diagnosis of Stage III periodontitis. Presence of at least two isolated interproximal intrabony defects located in different quadrants. Intrabony defect associated with a single-rooted tooth or mandibular molar without furcation involvement. Probing depth (PD) ≥ 6 mm. Radiographic intrabony defect depth between 3 and 7 mm. Absence of periapical pathology at the study site. Absence of acute periodontal infection. Absence of subgingival restorations that could interfere with clinical measurements. Absence of Grade II or Grade III tooth mobility. Ability and willingness to provide written informed consent. Exclusion Criteria: Pregnancy or lactation. Non-surgical periodontal therapy within the previous 6 months. Surgical periodontal therapy within the previous 12 months. History of radiotherapy to the head and neck region. Current smoking. Eligibility note: Former smokers and never-smokers are eligible.

Primary outcome measure(s)

  • Change in Probing Depth (PD) — Baseline and 6 months after treatment
    Change in periodontal probing depth (PD), measured in millimeters using a UNC-15 periodontal probe with a standardized probing force. Measurements are obtained using a patient-specific acrylic stent to ensure reproducibility.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry, Cairo University Giza Giza Governorate Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07836231 on ClinicalTrials.gov ↗ ← All trials in Egypt